**1. Business Performance:** Mankind Pharma's Q4 revenue grew 11.8% YoY to INR 3,443 Cr; FY26 revenue rose 17% to INR 14,278 Cr.

Q4 profit after tax surged 30.4% YoY to INR 559 Cr, though FY26 profit dipped 3.4%. Domestic business (ex-Consumer Healthcare) grew 13% in Q4, with chronic segment share increasing 190 bps in FY26. **2. Growth Drivers or Strategy:** The company pursues sustainable growth by specializing its base business, fast-growing chronic segments, high-potential OTC, and super specialty BSV portfolios.

Key strategies include new therapy expansion and increased R&D. **3. Recent Developments:** Mankind Pharma expanded offerings via strategic acquisitions, including Panacea (oncology/transplant) and Rivotril (CNS) from Roche.

It also secured EUGMP certifications for its Udaipur and Ambernath facilities. **4. Key Financial Metrics:** FY26 diluted EPS was INR 46.3. Adjusted EBITDA margins were 27.1% for Q4 and 25.9% for the full year.

Net Debt to EBITDA improved to 1.1x, and Adjusted ROCE stood at 41%. **5. Management Commentary / Outlook:** Management aims to consolidate market share in cardiovascular and chronic therapies.

Future plans involve expanding super specialty portfolios through M&A/in-licensing and continuous digital platform investments.